Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Inhibitor Therapeutics, Inc. (INTI) had Consolidated Net Income/Loss of $-0.73M for the most recently reported fiscal quarter, ending 2024-09-30.
| Income Statement Financials | |
-- |
|
$-0.73M |
|
-- |
|
-- |
|
$0.81M |
|
$-0.81M |
|
$0.08M |
|
$-0.73M |
|
$-0.73M |
|
$-0.73M |
|
$-0.73M |
|
|
Consolidated Net Income/Loss |
$-0.73M |
$-0.73M |
|
$-0.81M |
|
$-0.81M |
|
172.32M |
|
172.32M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$6.45M |
|
-- |
|
-- |
|
$6.45M |
|
$0.04M |
|
-- |
|
$3.00M |
|
$3.04M |
|
$3.41M |
|
$3.41M |
|
$3.41M |
|
172.32M |
|
| Cash Flow Statement Financials | |
$-2.46M |
|
-- |
|
-- |
|
$8.84M |
|
$6.38M |
|
$-2.46M |
|
$0.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
144.78 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.46% |
|
-21.46% |
|
-11.33% |
|
-21.46% |
|
$0.02 |
|
$-0.01 |
|
$-0.01 |
|